首页>
外文期刊>生殖与避孕:英文版
>Comparative Study on the Effects of Two Contraceptive Injections (Mesigyna, Cyclofem) on Blood Coagulation and Fibrinolysis
【24h】
Comparative Study on the Effects of Two Contraceptive Injections (Mesigyna, Cyclofem) on Blood Coagulation and Fibrinolysis
展开▼
机译:两种避孕药(Mesigyna,Cyclofem)对凝血和纤溶作用影响的比较研究
展开▼
免费
页面导航
摘要
著录项
相关主题
摘要
The effects of consecutively using the contraceptive injections (Mesigyna or Cy-clofem) on both blood coagulation and fibrinolysis were evaluated on 94 Chinese women who had been injected with one of these two injections once a month for 9 months. To provide the evidences on the safety of long-term use, relevant parame-ters were observed before the treatment, after the injection 3 and 9, as well as 3 months after drug withdrawing. The results were as follows: Among those who had been injected with Mesigyna, the levels of factor Ⅶ and factor Ⅹ declined signifi-cantly during treatment. The activity of AT- Ⅲ , plasminogen and the concentration of protein C also decreased. Moreover, the corresponding parameters did not recov-ered to the normal level after stopping treatment. Prothrombin time (PT) and acti-vated partial thromboplastin time (APTT) were prolonged in the early period of treatment, but recovered to the normal at week 47 (injection withdrawn).No or slight change was observed in other parameters. Among the woman injected with Cy-clofem, the concentrations of factor Ⅶ and plasminogen decreased over time, while the tissue plasminogen activator inhibitor (t-PAI) levels increased after the 9th injec-tion and recovered to normal at week 47 after discontinuation of treatment. The re-suits suggested that some significant parameter changes of coagulation and of fibri-nolysis could be detected among long-term users, but their impact on the fibrinolysis system was not obvious. The observed phenomenon did not show a tendency to facili-tate thromboembolism and possibility of being harmful to the users. Thus, the ob-served changes should be regarded as the reactions to keep the equilibrium between coagulation and fibrinolysis and had no marked clinical pathological significance on the users.
展开▼